For the Inventor, By the Inventor

Enter assignee name

Gaithersburg, MD, United States of America

Genvec, Inc.

USPTO Granted Patents = 88

% Expired Patents = 13.6

CIPO Patents = 3

EPO Patents = 17

Forward Citations = 1,794

Loading Chart...

Loading Chart...

43 inventors (with patents filed for the assignee):

Douglas E Brough (54 out of 58 patents)

Imre Kovesdi (54 out of 58 patents)

Duncan L McVey (37 out of 41 patents)

4. Joseph T Bruder (21 out of 25 patents)

5. Jason G D Gall (18 out of 20 patents)

6. Thomas J Wickham (18 out of 19 patents)

7. Petrus W Roelvink (10 out of 12 patents)

8. C Richter King (8 out of 24 patents)

9. Lisa Wei (5 out of 5 patents)

10. Jason Gall (5 out of 8 patents)

11. Alena Lizonova (5 out of 5 patents)

12. Marilyn Menger (5 out of 5 patents)

13. Damodar R Ettyreddy (4 out of 6 patents)

14. Ping Chen (4 out of 4 patents)

15. Miguel E Carrión (4 out of 4 patents)

Core Competencies:

Adenoviral Vectors

Gene Transfer

Malaria Vaccines

Herpes Simplex Virus

Therapeutic Regimen

Replication Deficient

Chimeric Vectors

Transgene Persistence

Viral Vector Library

Inhibitory Gene Products

Fluorescence Detection

Eukaryotic Viral Vectors

88 patents: Sort by Forward Citations

1. 11359214 - Simian (gorilla) adenovirus or adenoviral vectors and methods of use (2022-06-14),

2. 11279951 - Adenoviral vector encoding human atonal homolog-1 (HATH1) (2022-03-22),

3. 11155832 - Adenovectors for delivery of therapeutic genetic material into T cells (2021-10-26),

4. 11034975 - Affenadenovirus (gorilla) or adenoviral vectors and methods of use (2021-06-15),

5. 10947560 - Modified serotype 28 adenoviral vectors (2021-03-16),

6. 10792376 - Affenadenovirus (gorilla) or adenoviral vectors and methods of use (2020-10-06),

7. 10787682 - Simian (gorilla) adenovirus or adenoviral vectors and methods of use (2020-09-29),

8. 10780153 - Malaria antigens and methods of use (2020-09-22),

9. 10640776 - Method for propagating adenoviral vectors encoding inhibitory gene products (2020-05-05),

10. 10314901 - Malaria antigens and methods of use (2019-06-11),

11. 10272162 - Affenadenovirus (gorilla) or adenoviral vectors and methods of use (2019-04-30),

12. 10260074 - Affenadenovirus (gorilla) or adenoviral vectors and methods of use (2019-04-16),

13. 10125174 - Herpes simplex virus vaccine (2018-11-13),

14. 10059962 - Simian (gorilla) adenovirus or adenoviral vectors and methods of use (2018-08-28),

15. 10022432 - Malaria antigens and methods of use (2018-07-17),

Genvec, Inc., based in Gaithersburg, MD, specializes in the development of adenoviral vectors for gene transfer applications. The company focuses on innovative therapeutic regimens, particularly in the fields of malaria vaccines and herpes simplex virus treatments. Genvec's expertise includes the creation of replication-deficient and chimeric vectors, which enhance transgene persistence and efficacy. Through its advanced technologies, Genvec aims to address significant medical challenges and contribute to the advancement of gene therapy solutions.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

88 Patents

#2 in Gaithersburg, MD

#37 in Maryland

#4,232 in US

#8,668 in the World

Gaithersburg, MD, United States of America

Genvec, Inc.

Forward Citations = 1,794

43 inventors:

Douglas E Brough (54 out of 58 patents)

Imre Kovesdi (54 out of 58 patents)

Duncan L McVey (37 out of 41 patents)

4. Joseph T Bruder (21 out of 25 patents)

5. Jason G D Gall (18 out of 20 patents)

Please report any incorrect information to [email protected]

Loading…